Teleflex updates timelines for two business sales

Teleflex Incorporated outlines regulatory progress for two planned business divestitures.

Rhea-AI Filing Summary

Teleflex Incorporated outlines regulatory progress for two planned business divestitures. For its Original Equipment and Manufacturing and Development Services business, the Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern Time on March 13, 2026, and completion is anticipated in the third quarter of 2026, subject to remaining regulatory approvals and other conditions.

For its Acute Care and Interventional Urology businesses, Teleflex and Intersurgical Limited received Federal Trade Commission Second Requests on March 11, 2026, extending the HSR waiting period until 30 days after each has substantially complied. This transaction is currently anticipated to close in the second half of 2026, subject to regulatory approvals and specified conditions. The two transactions are separate and may close independently.

Insights

Regulatory and M&A analyst

One divestiture clears HSR waiting period while the other faces extended FTC review.

Teleflex plans to divest its OEM business to an affiliate of Montagu Private Equity and Kohlberg & Co., and its Acute Care and Interventional Urology businesses to Intersurgical Limited. The OEM deal passed the Hart-Scott-Rodino waiting period on March 13, 2026, a key U.S. antitrust milestone.

By contrast, the Acute Care and Interventional Urology deal triggered FTC Second Requests on March 11, 2026, automatically extending the HSR waiting period until 30 days after substantial compliance by both parties. Second Requests typically indicate deeper antitrust scrutiny, which can lengthen timelines and introduce conditional outcomes.

Teleflex now anticipates closing the OEM divestiture in the third quarter of 2026 and the Acute Care and Interventional Urology divestiture in the second half of 2026, with both transactions able to complete independently. Actual timing and terms will depend on remaining regulatory approvals and satisfaction of closing conditions.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What regulatory milestone did Teleflex (TFX) reach for its OEM business divestiture?

Teleflex achieved expiration of the Hart-Scott-Rodino waiting period for its OEM business sale at 11:59 p.m. Eastern Time on March 13, 2026. This satisfies one key closing condition, though additional regulatory approvals and other conditions must still be met before completion.

When does Teleflex expect to close the OEM business transaction?

Teleflex currently anticipates completing the OEM business transaction in the third quarter of 2026. This timing assumes remaining regulatory approvals are obtained and other closing conditions in the Equity Purchase Agreement with Lotus US Bidco Inc. are satisfied.

What happened in the FTC review of Teleflex’s Acute Care and Interventional Urology sale?

On March 11, 2026, Teleflex and Intersurgical Limited each received a Second Request from the Federal Trade Commission. These requests extend the Hart-Scott-Rodino waiting period, requiring substantial compliance by both parties before the review period can end.

How does the FTC Second Request affect the Acute Care and Interventional Urology transaction timeline?

Issuance of Second Requests extends the Hart-Scott-Rodino waiting period until 30 days after Teleflex and Intersurgical Limited each substantially comply. Teleflex currently expects this transaction to close in the second half of 2026, subject to approvals and conditions.

Are Teleflex’s OEM and Acute Care and Interventional Urology transactions linked?

Teleflex states that the OEM transaction and the Acute Care and Interventional Urology transaction are separate and may be consummated independently. Each has its own purchaser, conditions and regulatory review, so one transaction can close even if the other is still pending.

Who are the buyers in Teleflex’s planned divestitures?

The OEM business is being sold to Lotus US Bidco Inc., an affiliate of Montagu Private Equity LLP and Kohlberg & Co., L.L.C. The Acute Care and Interventional Urology businesses are being sold to Intersurgical Limited under a separate Equity Purchase Agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:45 PM Learn about SEC filing dates

0000096943false00000969432026-03-112026-03-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) March 11, 2026

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

Delaware			1-5353			23-1147939
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)

550 E. Swedesford Rd., Suite 400

Wayne,

PA

19087

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code

(610)

225-6800

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1 per share

TFX

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Original Equipment and Manufacturing and Development Services

As previously reported, on December 9, 2025, Teleflex Incorporated (the “Company”) entered into an Equity Purchase Agreement (the “OEM Agreement”) with Lotus US Bidco Inc. (the “OEM Purchaser”). The OEM Purchaser is a newly formed entity and an affiliate of Montagu Private Equity LLP and Kohlberg & CO., L.L.C.

The closing of the transactions contemplated by the OEM Agreement (the “OEM Transaction”) is subject to customary conditions, including the expiration or termination of any waiting period applicable to the consummation of the OEM Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”).

Effective as of 11:59 p.m. Eastern Time on March 13, 2026, the waiting period under the HSR Act with respect to the OEM Transaction expired, satisfying one of the conditions to the completion of the OEM Transaction.

The OEM Transaction is currently anticipated to be completed in the third quarter of 2026. The closing of the OEM Transaction remains subject to certain other regulatory approvals and conditions as set forth in the OEM Agreement.

Acute Care and Interventional Urology

As previously reported, on December 9, 2025, the Company also entered into an Equity Purchase Agreement (the “Acute Care and Urology Agreement”, and together with the OEM Agreement, the “Agreements”) with Intersurgical Limited (the “Acute Care and Urology Purchaser”).

The closing of the transactions contemplated by the Acute Care and Urology Agreement (the “Acute Care and Urology Transaction”) is subject to customary conditions, including the expiration or termination of any waiting period applicable to the consummation of the Acute Care and Urology Transaction under HSR Act.

On March 11, 2026, the Company and the Acute Care and Urology Purchaser each received a request for additional information and documentary material (each, a “Second Request”) from the U.S. Federal Trade Commission (the “FTC”) in connection with the FTC’s review of the Acute Care and Urology Transaction. Issuance of the Second Requests extends the waiting period under the HSR Act until 30 days after the Company and the Acute Care and Urology Purchaser have each substantially complied with the Second Request it received, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. The Company and the Acute Care and Urology Purchaser have been working cooperatively with the FTC and will continue to do so.

The Acute Care and Urology Transaction is currently anticipated to be completed in the second half of 2026.The closing of the Acute Care and Urology Transaction remains subject to regulatory approvals and certain other conditions set forth in the Acute Care and Urology Agreement.

The OEM Transaction and the Acute Care and Urology Transaction constitute separate transactions which may be consummated independently from one another.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.    

Date: March 17, 2026 TELEFLEX INCORPORATED

By: /s/ Daniel V. Logue Name: Daniel V. Logue Title: Corporate Vice President, General Counsel and Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB